Why the study?
Does weekly cyclophosphamide and epirubicin improve response rates in patients with metastatic breast cancer?
Does weekly cyclophosphamide and epirubicin improve response rates in patients with metastatic breast cancer?
Weekly cyclophosphamide and epirubicin is an active and well-tolerated first-line chemotherapy regimen for metastatic breast cancer.
May support first-line use in metastatic breast cancer; leaves open comparative efficacy versus standards in randomized trials.
Forty-six patients with metastatic breast cancer who had not received previous chemotherapy for advanced disease entered a phase II trial of weekly chemotherapy with cyclophosphamide (250 mg/m 2 ) + epirubicin (25 mg/m 2 ) for 16 weeks. The overall response rate was 61 % (95 % confidence limits, 47-75 %), with 10 complete and 17 partial responses. Toxicity was mild and confined to nausea and vomiting and asymptomatic neutropenia (except in 2 cases). Sixty-three per cent of patients had no side effects. Weekly cyclophosphamide + epirubicin is an active and nontoxic regimen for patients with metastatic breast cancer who have had no prior anthracycline-containing adjuvant chemotherapy.
No takes yet. Share an insight, caveat, or question.
Alba et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: